On 11 June 2026, Dingdang Health Technology Group Ltd. (Dingdang Health) filed a Next Day Disclosure Return detailing continued execution of its share repurchase mandate.

The company bought back 64,500 ordinary shares on-market at prices between HK$0.88 and HK$0.90, spending HK$0.06 million. All repurchased shares are earmarked for cancellation.

Since 19 May 2026, Dingdang Health has accumulated 8.89 million shares pending cancellation, acquired at volume-weighted prices ranging from HK$0.83 to HK$0.96 per share. The latest batch represents approximately 0.01% of the company’s 1.25 billion issued shares, while the total pending cancellation equals about 0.71% of the share capital.

Under the repurchase mandate approved on 28 May 2025, the company may buy back up to 131.95 million shares. Including the latest transactions, cumulative repurchases stand at 73.72 million shares, representing 5.59% of the shares outstanding when the mandate was granted.

The issued share count remains unchanged at 1.25 billion shares until the repurchased stock is formally cancelled. In accordance with Hong Kong listing rules, Dingdang Health is subject to a moratorium on new share issuance or treasury share sales until 11 July 2026.